Participants

Message from the Director Dear Friends of UCI MIND, Advances in the field of Alzheimer’s disease (AD) research and the contributions of UCI MIND investigators remain tremendously exciting. Two new drugs have been approved by the FDA (page 3). These approvals are believed by many to represent the dawn of a new age in AD research and treatment. Both drugs received accelerated approval and we await a decision from the FDA about “full approval” for lecanemab. If received, full approval could cause the Centers for Medicare and Medicaid Services to revisit their previous coverage decision about anti-amyloid antibody therapies. These…

The post MIND Matters | Quarterly Newsletter | Winter 2023 appeared first on UCI MIND.

Message from the Director Dear Friends of UCI MIND, As the fall MIND Matters newsletter goes to print, many of us are preparing to travel to San Francisco for the annual Clinical Trials in Alzheimer’s Disease (CTAD) meeting, where we will hear important results from recently completed Phase 3 clinical trials of potential new therapies for Alzheimer’s disease (AD). This includes trials of lecanemab (page 1) as well as other treatments. The topline results for lecanemab announced by the trial sponsors are exciting and suggest that lecanemab may slow the progression of AD. The availability of treatments to slow the…

The post MIND Matters | Quarterly Newsletter | Fall 2022 appeared first on UCI MIND.

Message from the Director Dear Friends of UCI MIND, We hope that you had a summer full of sun, fun, and good health. As you can see in this issue of MIND Matters, it has been a busy summer here at UCI MIND. Our investigators played a prominent role at the annual Alzheimer’s Association International Conference (AAIC), a focus of this issue (p 1, 3, 6, and 7). We’re very proud of our own Maria Corrada, ScD, who played a role in planning this important meeting (p 1 and 7), as well as the many researchers who presented their work….

The post MIND Matters | Quarterly Newsletter | Summer 2022 appeared first on UCI MIND.

Message from the Director Dear Friends of UCI MIND, Welcome to the new normal. COVID case numbers have surged again, but our research continues to push forward and our researchers have enthusiastically resumed in-person activities that have been few and far between over the last two years. This includes attending and holding scientific conferences, generally through hybrid formats, allowing those comfortable and ready to reconvene in-person to present new data, exchange ideas and forge new collaborations. Some UCI MIND investigators recently traveled to Barcelona, Spain to attend the International Conference on Alzheimer’s Disease and Parkinson’s Disease and related neurological disorders…

The post MIND Matters | Quarterly Newsletter | Spring 2022 appeared first on UCI MIND.

Message from the Director Dear Friends of UCI MIND, The COVID-19 surge caused by the Omicron variant has produced unwanted challenges for our research. Yet, our investigators remain unrelenting and highly successful in their work. Dr. Ira Lott received the international Trisomy 21 Research Society Montserrat Trueta Award (page 1). Dr. Claudia Kawas received the UCI Senate Better World Award (page 5). We honored Bob and Virginia Naeve with our UCI MIND Award, though we were unable to hold our A December to Remember Gala, to deliver it with the pomp and circumstance they deserve (page 7). Cherry Justice has…

The post MIND Matters | Quarterly Newsletter | Winter 2022 appeared first on UCI MIND.